Korim Index · Monthly analysis · Updated
What should Industrial & Manufacturing buyers pay more for: another specialist factory, or proof that it can remove a production bottleneck? For October, Korim’s commercial priority is the second. Focus acquisition work and supplier proposals on usable capacity, documented quality and integration costs. The investment case should explain which constraint disappears, how the buyer will measure that result and what must happen before additional equipment becomes dependable output.
Top opportunities this month
- Price the packaging qualification workload
Target pharmaceutical corporate development teams, technical operations directors and packaging quality leads with a fixed-scope acquisition diligence package.
- Stage capital against accepted defence output
Approach private equity investment teams, defence supplier finance directors and operations leaders with a staged capacity investment plan.
- Connect acquired factories before replacing systems
Offer industrial group operating partners, procurement directors and finance controllers a paid purchasing and inventory integration pilot across selected acquired sites.
Korim's view
Pay for control of a critical process, not simply ownership of more assets. Pharmaceutical packaging and defence components deserve close attention, but technical specialisation alone is an incomplete investment case. Assess value through accepted output, delivery reliability, working capital and the cost of bringing capacity into service. For software and industrial AI, apply the same discipline: buy a defined operational improvement, with an accountable owner and a measured baseline, rather than a broad transformation programme.
What changed this month
Production control frames the pharmaceutical case
Leading pharmaceutical companies have been acquiring end-to-end production capabilities to hedge against bottlenecks. Strategic pharmaceutical deal value through 15 November 2025 rose 79% compared with the same period in 2024. That is historical deal context, not an October growth rate or a measure of packaging demand. The commercial implication is to assess a manufacturing target by the production dependency it resolves, rather than applying a pharmaceutical deal narrative to every packaging asset.
Defence resilience needs a funding plan
In Q2 2026, aerospace and defence buyers shifted towards vertically integrated resilience, targeting critical inputs and mission-critical subsystems. October research identifies the capital needs of tier 2 and tier 3 defence suppliers: technology development, modernisation, bottleneck expansion and onshoring of critical inputs. Government procurement provides demand signals but does not finance capacity expansion. The analytical distinction is important: access to a programme and the means to manufacture for it are separate investment questions.
Packaging quality warrants diligence, not deadline selling
The US drug regulator’s August 2026 draft guidance sets out principles for evaluating drug and biological-product container closure quality, including systems that are device constituent parts of combination products. It remains non-binding and not for implementation. Use it as context for technical diligence and questions about the completeness of quality evidence. Do not convert it into a mandatory upgrade timetable or assume that every packaging manufacturer faces the same requirements.
Where the opportunity lies
Price the packaging qualification workload
Target pharmaceutical corporate development teams, technical operations directors and packaging quality leads with a fixed-scope acquisition diligence package. Deliver a product-to-process map, a review of customer qualification records, a quality evidence register and a costed plan for unresolved production constraints. Separate demonstrated capability from work still needed to support the buyer’s intended products. Assess value through the cost and time required to make the asset useful, not a blanket claim of defensible revenue. The buying trigger to seek is access to target records and agreement on the technical acceptance questions.
Stage capital against accepted defence output
Approach private equity investment teams, defence supplier finance directors and operations leaders with a staged capacity investment plan. Sell the engineering and financial work needed to connect equipment purchases, process readiness and customer acceptance. Deliver a bottleneck assessment, cash requirement schedule and milestone-based release of capital. Judge the proposal by accepted output at the constrained process and cash tied up before delivery. Avoid valuing installed machines as finished capacity. The next commercial signal is a supplier opening its production and order records for a jointly owned expansion assessment.
Connect acquired factories before replacing systems
Offer industrial group operating partners, procurement directors and finance controllers a paid purchasing and inventory integration pilot across selected acquired sites. Deliver a reconciled part catalogue, supplier records, stock definitions and an exception report before proposing wider system replacement. Measure reconciliation effort, purchasing exceptions and inventory accuracy against an agreed baseline. Keep industrial AI confined to reviewable assistance, such as suggesting duplicate records, until its accuracy is tested. The practical buying mechanism is a limited implementation contract with expansion tied to acceptance tests, rather than an assumed group-wide software commitment.
What could weaken the case
- Specialisation does not establish pricing power. Reject an acquisition premium where customer concentration, unresolved quality issues or required reinvestment undermine the return.
- Defence procurement signals are not supplier financing. Rework capacity plans where order timing, customer acceptance or funding availability fails to support the proposed investment sequence.
- Integration savings remain unproven until measured. Stop expansion where inconsistent records, weak site participation or correction costs outweigh the pilot’s operational benefit.
What to watch next
- Packaging: technical diligence requests that specify production constraints and quality records, rather than relying on broad market attractiveness.
- Defence: funded equipment plans with named acceptance owners and milestones connecting expenditure to usable output.
- Industrial software: pilot acceptance results and explicit approval from site operations before any wider purchasing commitment.
Research behind the analysis
Leading pharmaceutical companies are acquiring end-to-end production capabilities to hedge against bottlenecks, while strategic pharma deal value through 15 November 2025 rose 79% compared with the same period in 2024.
Bain & Company ·The FDA’s August 2026 draft guidance sets out principles for evaluating the quality of drug and biological-product container closure systems, including those that are device constituent parts of combination products, but remains non-binding and not for implementation.
FDA ·In Q2 2026, aerospace and defence buyers shifted towards vertically integrated resilience, targeting critical inputs and mission-critical subsystems.
KPMG ·Upstream tier 2 and tier 3 defence suppliers require capital to develop technologies, modernise capabilities, scale up bottlenecks and onshore critical inputs, while government procurement provides demand signals but does not finance capacity expansion.
BCG ·